Index - P/E - EPS (ttm) -22.15 Insider Own 0.00% Shs Outstand 137.26M Perf Week -1.02%
Market Cap 20.04M Forward P/E - EPS next Y -10.45 Insider Trans - Shs Float 137.25M Perf Month -51.37%
Income -149.01M PEG - EPS next Q -2.93 Inst Own 0.51% Short Float 0.34% Perf Quarter -79.07%
Sales 12.46M P/S 1.61 EPS this Y 47.76% Inst Trans 118.70% Short Ratio 0.02 Perf Half Y -97.55%
Book/sh 4.28 P/B 0.03 EPS next Y 27.29% ROA -129.55% Short Interest 0.47M Perf Year -99.38%
Cash/sh 0.03 P/C 4.82 EPS next 5Y - ROE -163.24% 52W Range 0.13 - 26.56 Perf YTD -98.87%
Dividend Est. - P/FCF - EPS past 5Y 79.31% ROI -308.74% 52W High -99.45% Beta 2.09
Dividend TTM - Quick Ratio 0.72 Sales past 5Y 0.00% Gross Margin -17.61% 52W Low 12.31% ATR (14) 0.04
Dividend Ex-Date - Current Ratio 1.15 EPS Y/Y TTM -61.43% Oper. Margin -764.06% RSI (14) 27.27 Volatility 5.23% 13.99%
Employees 103 Debt/Eq 0.22 Sales Y/Y TTM - Profit Margin -1196.11% Recom 1.00 Target Price 21.00
Option/Short No / Yes LT Debt/Eq 0.15 EPS Q/Q -619.99% Payout - Rel Volume 9.63 Prev Close 0.14
Sales Surprise -36.91% EPS Surprise -489.01% Sales Q/Q - Earnings Aug 19 BMO Avg Volume 21.38M Price 0.15
SMA20 -8.04% SMA50 -57.91% SMA200 -97.51% Trades Volume 206,017,682 Change 6.88%
Date Action Analyst Rating Change Price Target Change
Apr-18-22 Initiated Noble Capital Markets Outperform
Apr-18-19 Upgrade ROTH Capital Neutral ? Buy $4
Aug-18-17 Upgrade ROTH Capital Neutral ? Buy $6
Sep-07-16 Downgrade ROTH Capital Buy ? Neutral
Feb-17-16 Reiterated Oppenheimer Outperform $18 ? $10
Nov-04-15 Initiated Cantor Fitzgerald Buy
Jun-12-15 Initiated Oppenheimer Outperform $18
Feb-17-15 Reiterated ROTH Capital Buy $10 ? $12
Sep-29-14 Reiterated ROTH Capital Buy $17 ? $10
Today 07:00AM
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines
(GlobeNewswire)
+6.88%
Sep-23-24 07:00AM
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024)
(GlobeNewswire)
-8.54%
Sep-19-24 07:00AM
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
(GlobeNewswire)
Sep-18-24 07:30AM
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
(ACCESSWIRE)
Sep-16-24 07:00AM
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
(GlobeNewswire)
-5.93%
01:00PM
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Finviz Elite
Sep-11-24 01:00PM
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
(ACCESSWIRE)
Sep-10-24 07:00AM
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations
(GlobeNewswire)
-6.12%
Sep-09-24 07:00AM
Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Talk at Immunology Symposium at the University of Alberta
(GlobeNewswire)
+15.86%
Sep-06-24 07:00AM
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
(GlobeNewswire)
-10.26%
Sep-04-24 07:00AM
As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL
(ACCESSWIRE)
Aug-29-24 07:00AM
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-14.82%
Aug-28-24 07:00AM
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-17.37%
Aug-26-24 10:41AM
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
(Benzinga)
+10.00%
07:00AM
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801
(GlobeNewswire)
Aug-23-24 07:45AM
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
(ACCESSWIRE)
07:00AM
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Finviz Elite
Aug-21-24 07:00AM
Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-5.26%
Aug-20-24 12:34PM
Tonix initiates Phase II trial for emergency cocaine intoxication treatment
(Clinical Trials Arena)
-14.61%
07:00AM
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
(GlobeNewswire)
Aug-19-24 06:00AM
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire)
Aug-16-24 10:52PM
TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
(InvestorPlace)
01:29PM
Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
(Benzinga)
07:00AM
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
(GlobeNewswire)
Aug-13-24 08:00AM
Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
(GlobeNewswire)
Aug-12-24 08:00AM
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
(GlobeNewswire)
+7.00%
Aug-06-24 08:00AM
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company's Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
(GlobeNewswire)
Aug-01-24 07:45AM
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
(ACCESSWIRE)
Jul-31-24 08:00AM
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya
(GlobeNewswire)
-12.23%
Jul-30-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
(GlobeNewswire)
Jul-29-24 09:00AM
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
(PR Newswire)
Jul-25-24 08:30AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
(GlobeNewswire)
+9.96%
08:00AM
Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.
Finviz Elite
08:00AM
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia
(GlobeNewswire)
Jul-24-24 07:45AM
Beyond 'One Bug, One Drug' - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
(ACCESSWIRE)
-7.19%
Jul-22-24 07:00AM
7 Sorry Biotech Stocks Set to Make Investors Sad
(InvestorPlace)
Jul-19-24 12:48PM
Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence
(News Direct)
Jul-18-24 10:20AM
Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya for fibromyalgia management
(News Direct)
Jul-17-24 08:00AM
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
(ACCESSWIRE)
Jul-10-24 04:30PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
Jul-09-24 09:15AM
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
(GlobeNewswire)
-15.47%
07:39AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
Jul-08-24 05:00PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
-10.96%
08:00AM
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
07:00AM
7 F-Rated Stocks To Sell in July
(InvestorPlace)
Jul-01-24 11:07AM
Nano-Cap Tonix Pharmaceuticals Secures Large US Department of Defense Contract
(Benzinga)
08:00AM
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
(GlobeNewswire)
Jun-28-24 04:05PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
Jun-27-24 11:01AM
AMZN Stock Alert: Amazon Just Joined the $2 Trillion Club
(InvestorPlace)
-38.67%
08:37AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
(InvestorPlace)
08:36AM
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
(GlobeNewswire)
07:34AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
(InvestorPlace)
Jun-26-24 04:40PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
-10.00%
03:13PM
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Jun-25-24 08:00AM
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
(GlobeNewswire)
+5.04%
Jun-21-24 07:30AM
7 F-Rated Penny Stocks to Avoid This June
(InvestorPlace)
Jun-20-24 08:00AM
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
+10.66%
Jun-18-24 12:31PM
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
(InvestorPlace)
+8.93%
08:00AM
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
(GlobeNewswire)
Jun-17-24 08:00AM
Tonix Pharmaceuticals Presented Poster of Tonmya for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
(GlobeNewswire)
Jun-13-24 05:00PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
+5.50%
Jun-12-24 10:06AM
FedEx Layoffs 2024: What to Know About the Latest FDX Job Cuts
(InvestorPlace)
-47.89%
09:00AM
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
(GlobeNewswire)
08:52AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today?
(InvestorPlace)
07:46AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
(InvestorPlace)
Jun-11-24 05:17PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
10:26AM
Tonix Pharmaceuticals Nears Market Entry with Tonmya for Fibromyalgia Management
(News Direct)
Jun-10-24 12:14PM
SOUN Stock Alert: SoundHound AI Pays Off Debt Early
(InvestorPlace)
-33.66%
11:55AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
(InvestorPlace)
Jun-06-24 11:00AM
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
(GlobeNewswire)
-28.04%
08:00AM
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
(GlobeNewswire)
Jun-05-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
(GlobeNewswire)
Jun-03-24 08:00AM
Tonix Pharmaceuticals Presented New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting
(GlobeNewswire)
May-30-24 08:00AM
Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting
(GlobeNewswire)
May-29-24 08:00AM
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
(GlobeNewswire)
May-28-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
(GlobeNewswire)
May-22-24 08:00AM
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
(GlobeNewswire)
May-21-24 08:00AM
Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
May-20-24 10:53AM
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace)
May-15-24 08:00AM
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
(GlobeNewswire)
May-13-24 04:30PM
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire)
+5.20%
Apr-29-24 09:00AM
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
(ACCESSWIRE)
+6.53%
Apr-24-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
(GlobeNewswire)
Apr-09-24 06:31AM
3 Biotech Stocks to Dump Before They Go to Zero
(InvestorPlace)
Apr-01-24 04:15PM
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
(GlobeNewswire)
Mar-28-24 09:32AM
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
(GlobeNewswire)
-43.10%
Mar-25-24 08:00AM
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
(GlobeNewswire)
-5.20%
Mar-24-24 04:05PM
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
(InvestorPlace)
Mar-21-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
(GlobeNewswire)
Mar-20-24 08:00AM
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
Mar-19-24 08:00AM
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
(GlobeNewswire)
Mar-12-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
(GlobeNewswire)
-8.86%
Mar-11-24 08:00AM
Tonix Pharmaceuticals Reports Improvement in Brain Fog, in Fibromyalgia Patients Treated with Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
(GlobeNewswire)
Mar-07-24 09:37AM
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
(GlobeNewswire)
08:00AM
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
(GlobeNewswire)
Mar-06-24 08:00AM
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
Mar-05-24 08:00AM
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
(GlobeNewswire)
Feb-29-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
(GlobeNewswire)
Feb-28-24 08:00AM
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
(GlobeNewswire)
06:56AM
Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial
(News Direct)
06:54AM
Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation
(News Direct)
Feb-27-24 08:00AM
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya to Support Development and Partnering in Japan and China
(GlobeNewswire)
+6.88%
Feb-26-24 08:00AM
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
(ACCESSWIRE)
+6.93%
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
Income Statement • Balance Sheet • Cash Flow
Data
YoY Growth
YoY Growth %
Timeframe
Annual
Quarterly
Period End Date TTM 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Period Length 12 Months 12 Months 12 Months
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.
Learn more
Total Revenue
12.46 7.77 0.00
Cost of Goods Sold Incl. D&A
14.65 9.03 1.25
Gross Profit
-2.19 -1.26 -1.25
Selling, General and Administrative Excl. Other
92.99 117.12 110.84
Research and Development
60.73 86.66 81.88
Other Operating Expense
0.00 0.00 0.00
Operating Income
-95.19 -118.38 -112.09
Interest Expense
0.00
Unusual Expense
52.81 -0.30 0.00
Net Income Before Taxes
-149.01 -116.66 -110.22
Income Taxes
0.00 0.00 0.00
Consolidated Net Income
-149.01 -116.66 -110.22
Net Income From Continuing Operations
-149.01 -116.66 -110.22
Net Income
-149.01 -116.66 -116.88
EPS (Recurring)
-27.43 -6.86 -20.44
EPS (Basic, Before Extraordinaries)
-22.15 -6.85 -20.44
EPS (Diluted)
-22.15 -6.85 -20.44
EBITDA
-90.30 -114.09 -110.84
Price To Earnings Ratio
-0.01 -0.01 -1.15
Price To Sales Ratio
0.23 0.88
Gross Margin
-17.61 -16.27
Operating Margin
-764.06 -764.06 -3,103.01
Net Margin
-1,196.11 -1,501.78
Shares Outstanding
9.83 58.61 12.24
Market Capitalization
18.75 18.75 755.89
values in Millions, USD
open in yahoo
|
open in reuters
|
open in marketwatch
|
open in google
|
open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.
AI
